Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03710603 · OUTCOME

Pharmacokinetic Concentrations of Daratumumab

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma · Source last updated 2026-02-10

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
From randomization to the clinical cutoff date. Maximum follow up was 54.41 months

What was measured

Pharmacokinetic concentrations of daratumumab

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
Pharmacokinetic concentrations of daratumumab
reporting Status
NOT_POSTED
time Frame
From randomization to the clinical cutoff date. Maximum follow up was 54.41 months
title
Pharmacokinetic Concentrations of Daratumumab
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice